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Physicians who adhered to “evidence-based 
practice” principles — defined as identifying 
research evidence as “the best source” for 
informing clinical decision-making — were 
significantly less likely to prescribe off label.
Assessing the risks of  
off-label prescribing
Although some drugs prescribed off-label are done so appropriately, most 
of the off-label prescribing in Canada doesn’t have a scientific basis.
— A researcher1 
In Canada, before any medication is approved for sale, Health Canada’s Therapeutic Products Directorate must review its safety and effectiveness.2 Scientists at this agency review data 
provided by the drug’s manufacturer. If benefits are found to 
outweigh risks, and if these risks can be reasonably mitigated, then 
the manufacturer is permitted to sell the drug.2 
However, once a drug is approved for sale, physicians are not 
restricted as to how they prescribe it. Instead, they may prescribe for 
both conditions and populations for which the drug has not been 
approved. For example, a physician may prescribe a drug to a child or youth  
even though the drug is approved for use only in adults. This practice is known  
as “off-label” prescribing.3
Frequency of off-label psychiatric prescribing 
Recent population-based studies have found that young people frequently 
receive off-label psychiatric prescriptions. For example, a nationwide study of 
German children documented that more than a third of all psychiatric drugs were 
prescribed off label, with antipsychotic and antidepressant prescriptions of this 
type being particularly high.4 Similarly, a nationwide study of Icelandic children 
documented that a quarter of all psychiatric drugs were prescribed off label, with 
off-label hypnotics/sedative, antipsychotic and antidepressant prescribing being 
particularly common.5
Off-label psychiatric prescribing for children and youth is also common in 
North America. One US study tracked outpatient antidepressant prescriptions 
for six- to 18-year-olds and found that 91% were off-label.6 These off-label 
uses included prescribing antidepressants that were not approved for pediatric 
populations and prescribing them for non-indicated conditions, such as 
attention-deficit/hyperactivity disorder (ADHD).6 Two Canadian studies, 
examined in detail in the upcoming Review article, also found high rates of  
off-label antipsychotic prescribing.7, 8
The usual safety and 
efficacy data, required for 
medications to receive  
“on-label” approval, are often 
lacking for off-label uses.
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What’s the problem with off-label  
psychiatric prescribing?
There are several concerns about off-label psychiatric prescribing for children 
and youth. Foremost, often limited information exists about potential harms. 
These harms may include side effects such as negative consequences for growth 
and development, as well as adverse health events such as the development of 
cardiovascular problems associated with certain antipsychotics in young  
people.9, 10 Information is limited because the usual safety and efficacy data, required 
for medications to receive “on-label” approval, are often lacking for off-label uses.3
This is not the only concern. When physicians are willing to prescribe off 
label, drug companies may have little motivation to invest in costly clinical trials 
with children and youth. Consequently, off-label prescribing may inadvertently 
undermine the goal of conducting rigorous safety and efficacy studies in children 
and youth.
Off-label prescribing can also add financial costs. For example, when physicians 
prescribe newer and more expensive off-label drugs over older and less costly 
alternatives, health care costs increase — for individuals and for society collectively.3 
Finally, off-label prescribing can erode public trust in physicians and the health 
care system — because parents receiving a prescription for their child expect that 
the drug’s safety and efficacy have been comprehensively evaluated, but this is not 
assured for off-label uses.3
Making careful clinical decisions 
Given the concerns with off-label prescribing, why does this practice persist? One 
crucial reason is that very few psychiatric medications have Health Canada approval 
for pediatric use. Schizophrenia and bipolar disorder are two disorders that illustrate 
why physicians may have to resort to off-label prescribing. Physicians have long 
needed antipsychotic medications to treat psychosis and mania, given the severe 
and disabling symptoms associated with these two disorders. Yet only one newer 
antipsychotic (aripiprazole) has been approved by Health Canada for pediatric 
use, and this approval was only granted in 2009.13 Consequently, before 2009, all 
prescribing of newer antipsychotics for Canadian young people was effectively off-
label. Even now, many newer antipsychotics have yet to receive regulatory approval. 
Fortunately, there is another source of information besides Health Canada to 
guide clinical decision-making. Physicians can turn to the best available research 
evidence — randomized controlled trials published in peer-reviewed journals — to 
guide their practice while waiting for Health Canada approvals. For example, many 
physicians would feel compelled — clinically and ethically — to prescribe off label 
newer antipsychotics for youth with schizophrenia and bipolar disorder, given the 
gravity of these disorders. In these situations, physicians can use research evidence 
to help guide their selection of a particular antipsychotic. 
the need for enforcement
in 2009, the Us government issued what was then its largest-ever criminal fine in 
a health care case.11 the pharmaceutical 
conglomerate eli lilly agreed to pay 
more than $1.4 billion for promoting its 
antipsychotic, olanzapine (sold under 
the trademark name Zyprexa), for uses 
not approved by the Food and drug 
administration.11 the company’s marketing 
campaign aimed at doctors — “Viva 
Zyprexa” — was specifically found to 
promote the use of this drug in children 
and adolescents, despite its lack of 
any pediatric approval.12 as part of the 
settlement, eli lilly had to comply with close 
ongoing monitoring of its marketing and 
sales practices.11 While this case illustrates 
the potential for deliberate abuses of the 
drug approval process, it also illustrates the 
potential for regulatory agencies to enforce 
their guidelines and rectify abuses by 
pharmaceutical companies.
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What makes physicians less likely  
to prescribe off label?
At times, however, neither regulatory approvals nor the research evidence guides 
prescribing practices. To better understand why this occurs, Canadian researchers 
have studied the characteristics of those physicians who were more likely to 
prescribe off label. They found only one characteristic that mattered. Physicians 
who adhered to “evidence-based practice” principles — defined as identifying 
research evidence as “the best source” for informing clinical decision-making — 
were significantly less likely to prescribe off label, especially when the research 
evidence was also weak.14
Improving safety
Several remedies can mitigate the potential harms of off-label psychiatric 
prescribing for children and youth. More high-quality pediatric medication trials 
are a crucial first step — to determine efficacy and safety of specific medications 
for young people. As part of this, governments can mandate that pharmaceutical 
companies study medications in young people as part of the approval process. 
For example, the US Congress and the European Parliament passed 
legislation requiring manufacturers who anticipate their medications being used 
in pediatric populations to conduct studies and submit results to regulatory 
bodies in advance, in return for six-month extensions of market exclusivity.15 
These incentives resulted in more pediatric drug studies and more attention to 
delineating pediatric indications and dosing.15 However, when this approach 
was tried in Canada, its success was quite limited. The relatively small size of 
the Canadian market likely played a role in few manufacturers submitting the 
necessary data for Canadian pediatric indications and dosing.15 Consequently, 
additional strategies may be needed, such as international harmonization of laws 
promoting pediatric research.15
Monitoring is another way to try to improve safety. With this goal in mind, 
the World Health Organization (WHO) promotes the reporting of medication-
related problems among the 139 countries participating in its Programme for 
International Drug Monitoring.16 Member countries (including Canada) forward 
data from their national drug monitoring centres to the organization.10 The  
WHO then compiles and disseminates information on the risk-benefit profiles  
of all medicines, including psychiatric medications used in young people.16
Addressing the concerns associated with off-label psychiatric prescribing for 
children and youth will likely require multiple approaches — including new 
legislation and new studies. Meanwhile, physicians will have to continue to rely 
on high-quality research evidence and on ongoing monitoring programs to ensure 
that the medications they prescribe for children and youth are both safe and 
effective.
Addressing the concerns 
associated with off-label 
psychiatric prescribing for 
children and youth will likely 
require multiple approaches 
— including new legislation 
and new studies.
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Problematic patterns in 
antipsychotic prescribing
Of the approximately 800,000 Canadian children and youth who experience mental disorders at any given time, many will be prescribed psychiatric medications, or psychotropics.17 But how many of these 
prescriptions are appropriate — regarding either “on-label” uses approved by 
Health Canada or uses supported by the best available research evidence? 
To answer these questions, we identified: 1) studies on psychotropics 
prescribed to Canadian children and youth, including the psychiatric conditions 
these medications were prescribed for; 2) Health Canada approvals for the most 
commonly prescribed psychotropics identified in these studies; and 3) the best 
available research evidence on these psychotropics and their uses in children  
and youth.
Identifying the evidence
First, we searched for studies on all psychotropics being prescribed for young 
people in Canada. Three studies met our inclusion criteria: one from BC 8 and 
two from Manitoba.7, 18 All three assessed antipsychotics only. Because there was 
considerable overlap between the two Manitoba studies, we selected the more 
recent, which was not only more current but also more comprehensive. 
Next, we conducted searches of Health Canada’s website to 
determine the approval status for the antipsychotics identified in 
these two studies. We limited our searches to “second-generation”  
or “newer” antipsychotics, because these constituted the vast 
majority of antipsychotic prescriptions written for children and 
youth in recent years in BC and Manitoba.7, 8 (The sidebar provides 
more information on these medications.)
Finally, we identified the best available research evidence on 
newer antipsychotics in children and youth. More specifically, 
for these medications, we searched for published double-blind 
randomized controlled trials (RCTs) showing positive outcomes 
related to a specific diagnosis in children or youth. We also required 
that there be at least two RCTs, one with placebo controls, meeting 
these criteria to classify a medication as being “supported by the 
research evidence.” (Our Methods provide further information  
on these three searches.) 
Both studies uncovered striking increases  
in the number of antipsychotic prescriptions 
written and dispensed for children and 
youth.
a different kind of generation gap
antipsychotics have sometimes been described as either first- or second-generation. the first-generation 
antipsychotics — also known as “typical” or “older” 
antipsychotics — were introduced in the 1950s. since 
their arrival on the market, they have been associated with 
a host of disturbing side effects, particularly neurological 
problems. When second-generation antipsychotics — also 
known as “atypical” or “newer” antipsychotics — became 
available in Canada in the 1990s, they were heralded as 
being equally effective but without the same problematic 
side effects.18 now, however, troubling side effects for 
newer antipsychotics are also emerging — including 
significant weight gain, altered blood glucose and lipids, 
and high blood pressure.19 Consequently, many researchers 
now suggest carefully weighing the risks and benefits for 
all antipsychotics before prescribing, based on their specific 
efficacy and side effect profiles.20 
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Antipsychotic prescribing in BC and Manitoba
The BC and Manitoba studies both tracked all antipsychotic prescriptions  
written and dispensed for children and youth (birth through 18 years) using 
comprehensive provincial health databases.7, 8 BC researchers tracked these 
prescriptions for 15 years (1996–2011), and Manitoba researchers tracked them  
for 10 years (1998–2008). Both studies included all outpatient prescriptions;  
the Manitoba study also included inpatient prescriptions.
Both studies uncovered striking increases in the number of antipsychotic 
prescriptions written and dispensed for children and youth. In BC, these 
prescriptions increased nearly fourfold between 1996 and 2011.8 Similarly in 
Manitoba, these prescriptions increased three- to fourfold between 1999 and 2008.7
Notably, most of these prescribing increases were accounted for by newer 
antipsychotics, with these comprising approximately 95% of all antipsychotic 
prescriptions written for children and youth by the end of both studies.7, 8 Three 
particular newer antipsychotics — risperidone, quetiapine and olanzapine — were 
the ones most frequently prescribed in both studies.7, 8 Other second-generation 
antipsychotics tracked were aripiprazole, clozapine, paliperidone and ziprasidone. 
The sidebar provides the Canadian trademark names for these seven antipsychotics. 
Both studies also linked antipsychotic prescribing with diagnoses. In the 
final year of each study (the only year reported here, to reflect the most current 
practices), antipsychotics were most frequently prescribed for: 
•	 Depression,	attention-deficit/hyperactivity	disorder	(ADHD)	and	anxiety	in	 
BC children and youth8
•	 ADHD,	conduct	disorders	(including	oppositional	defiant	disorder	or	ODD)	
and tic disorders in Manitoba children and youth7
Table 1 outlines further findings from the two studies.
Table 1: Antipsychotic Prescribing in BC and Manitoba  
 BC Manitoba
 
* Prescriptions and diagnoses are only listed for the final year of the study to reflect most current practices.
**  data reflect increases over the duration of the studies in both second- and first-generation antipsychotic prescriptions; however, 
the latter constituted only a tiny minority (under 5%) of prescriptions in the final study years.   
study years 
Participant ages
data sources
 
Antipsychotics most 
frequently prescribed * 
 
Diagnoses most frequently 
linked to antipsychotic 
prescribing *
Increases in antipsychotic 
prescribing *  * 
1998 – 2008 (10 years)
Birth through 18 years
drug Program information network 
(all outpatient & inpatient prescriptions)
•  Risperidone  (63.6%)
•  Quetiapine  (20.6%)
•  Olanzapine  (10.2%)
•  Attention-deficit/hyperactivity disorder 
•  Conduct & oppositional defiant disorders 
•  Tic disorders 
3.2- & 4.1-fold 
(females & males, respectively)
1996 – 2011 (15 years)
Birth through 18 years
Pharmanet database 
(all outpatient prescriptions)
•  Risperidone  (48.0%)
•  Quetiapine  (36.2%)
•  Olanzapine  (5.9%)
•  Depression
•  Attention-deficit/hyperactivity disorder
•  Anxiety disorders
3.8-fold 
(both males & females)
a medication by any other name
the second-generation antipsychotics featured in the review article are all 
identified by their generic names. each 
one is also sold under a trademark name. 
the following table identifies the Canadian 
trademark names associated with each  
generic formulation.21
Generic Name Trademark Name
aripiprazole  abilify
clozapine  Clozaril
olanzapine  Zyprexa
paliperidone  invega
quetiapine  seroquel
risperidone  risperidal
ziprasidone  Zeldox
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Which newer antipsychotics  
have regulatory approval?
We sought to determine whether the prescribing patterns found in BC and 
Manitoba were consistent with regulatory approval for newer antipsychotics 
sold in Canada. Because approval status was identified only in the Manitoba 
study, and because approvals changed after this study finished, we independently 
identified the current approval status for the seven second-generation 
antipsychotics tracked in the studies. We found that only aripiprazole is approved 
for pediatric use (granted in 2009). Furthermore, aripiprazole is approved only 
for older youth with one of two conditions: bipolar disorder (13- to 17-year-olds) 
or schizophrenia (15- to 17-year-olds). Health Canada currently labels all other 
newer antipsychotics as lacking established safety and efficacy for anyone under 
age 18 years.2 (Please see our Methods for more details on our approaches for 
determining Health Canada approval.)
What the research evidence suggests
Beyond the question of off-label use, were the prescribing patterns in BC 
and Manitoba consistent with the best available research evidence on newer 
antipsychotics? Because both studies provided limited information about this 
question, we conducted a comprehensive search to identify the best available 
research evidence on the effectiveness of these antipsychotics in children and 
youth. (Again, please see our Methods and the sidebar for details on our 
approaches.)
We found high-quality research evidence supporting the 
use of four newer antipsychotics for treating specific mental 
disorders or symptoms in children or youth. Aripiprazole 
reduced challenging secondary behaviours associated with 
autism spectrum disorder (e.g., hyperactivity and repetitive 
behaviours) in children and youth.22, 23 It also reduced core 
symptoms of bipolar disorder (i.e., mania) in youth.24, 25 
Olanzapine reduced core symptoms of schizophrenia (i.e., 
psychosis) in youth.26–28 Quetiapine reduced core symptoms 
of bipolar disorder 29, 30 and conduct disorder (i.e., aggressive 
behaviour) in youth.31, 32 Finally, risperidone reduced 
challenging secondary behaviours associated with autism 
spectrum disorder in children and youth.33–37 It also reduced 
core symptoms of bipolar disorder and schizophrenia in youth 
as well as core symptoms of conduct, oppositional defiant and 
tic disorders in children and youth.27, 28, 38–46 
our standards for defining high-quality research
the goal of the Quarterly is to provide summaries of high-quality research evidence on children’s mental health 
topics. While our inclusion criteria vary slightly depending on the 
quality and quantity of research for any given topic, when we 
assess how well an intervention works, we rely on randomized 
controlled trials (rCts). We do so because rCts allow us (and 
others) to be sure that if children experienced improvements, 
it was due to the intervention rather than other factors such as 
chance. in this particular issue, we also outline an added criterion 
for classifying medications as being “supported by the research 
evidence.” namely, we required two or more published double-
blind rCts, including one with placebo controls, showing positive 
results in children or youth. We added this criterion because 
double-blind, placebo-controlled rCts allow us (and others) to 
be sure that if children experienced improvements, it was due to 
medication rather than other factors, such as children’s, parents’ 
or researchers’ expectations that the medication would work.
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Table 2 summarizes our research findings. Specifically, four newer 
antipsychotics have been shown to be effective in treating five specific mental 
disorders in children and youth. Where other newer antipsychotics and other 
mental disorders are not listed, it means that we found insufficient high-quality 
research evidence supporting the medications’ use.
Table 2: Newer Antipsychotics: Research Evidence on Effectiveness in Children and Youth
Medication Disorders where medication is effective* 
* the medication has been studied in 2+ published double-blind randomized controlled trials, including 1 with placebo 
controls. each trial showed positive outcomes related to these specific disorders or symptoms in children or youth. 
**  this medication has health Canada approval for treating youth with either bipolar disorder or schizophrenia.
aripiprazole**
 
Olanzapine
Quetiapine
 
risperidone
•  Autism spectrum disorder (associated challenging behaviours) in children and youth22, 23
•  Bipolar disorder (core symptoms) in youth24, 25
•  Schizophrenia (core symptoms) in youth26–28
•  Bipolar disorder (core symptoms) in youth29, 30
•  Conduct disorder (core symptoms) in youth31, 32
•  Autism spectrum disorder (associated challenging behaviours) in children and youth33–37
•  Bipolar disorder (core symptoms) in youth38, 39
•  Conduct and oppositional defiant disorder (core symptoms) in children and youth41–44
•  Schizophrenia (core symptoms) in youth27, 28, 40 
•  Tic disorder (core symptoms) in children and youth45, 46
How does current prescribing compare  
with regulations and research? 
Returning to the BC and Manitoba findings, to summarize, the top three 
antipsychotics being prescribed in each province (in the final study year) were 
risperidone, quetiapine and olanzapine (all newer antipsychotics). Meanwhile, 
the top mental disorders being treated with these medications (in the final study 
year) were depression, ADHD and anxiety in BC; and ADHD, conduct disorders 
(including ODD) and tic disorders in Manitoba. While other antipsychotics 
were also used and other disorders were also treated, these were by far the most 
common medications and uses. So how do these pediatric prescribing patterns 
compare with both the regulatory approvals and the research evidence? 
Regarding regulatory approvals, Health Canada lists only aripiprazole 
— which was approved for treating youth with bipolar disorder or schizophrenia 
in 2009. Therefore, according to these BC and Manitoba studies, almost all newer 
antipsychotic prescribing for Canadian children and youth was off-label.
But a different picture emerges when we examine the best available research 
evidence on the newer antipsychotics. As outlined in Table 2, the research 
evidence suggests that four newer antipsychotics can be effective in pediatric 
populations: aripiprazole, olanzapine, quetiapine and risperidone. The research 
evidence also suggests very particular indications for these medications (i.e., 
bipolar disorder, schizophrenia, autism spectrum disorder, and conduct or tic 
Four newer antipsychotics 
have been shown to be 
effective in treating five 
specific mental disorders in 
children and youth.
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disorder). The research evidence therefore points — with considerable specificity 
— to which newer antipsychotics may indeed be appropriate for which disorders. 
How do the BC and Manitoba findings overlap with this research evidence? 
Unfortunately, the studies’ authors did not specify which medications were 
specifically prescribed for which disorders. So it is not possible to draw 
conclusions beyond looking at the top three medications and the top diagnoses.
When we examine the top three antipsychotics being prescribed, there is 
high-quality research evidence supporting the use of each of them, but only for 
specific purposes. It is therefore possible that these three medications may have 
constituted appropriate choices — if they were used for the specific purposes 
noted in Table 2. However, it is not clear why there would be three- to four-fold 
increases in these prescriptions for children and youth in recent years. These 
increases are quite remarkable given that there is no evidence from high-quality 
epidemiological studies of similar increases in the prevalence of pediatric mental 
disorders during this time.17, 47, 48 These prescription increases are therefore highly 
concerning because they strongly suggest that research evidence was not the 
primary factor guiding off-label antipsychotic prescribing.
Identifying treatments backed by research evidence
Of even greater concern, newer antipsychotics are not recommended for treating 
three of the top five diagnoses identified in the BC and Manitoba studies 
(depression, ADHD and anxiety) in young people. Instead, for depression, 
CBT, interpersonal psychotherapy and adjunctive antidepressant medication 
(i.e., fluoxetine) are highly effective 49, 50 For ADHD, stimulant medications 
(methylphenidate, dextroamphetamine and atomoxetine) as well as behavioural 
therapy and parent training are highly effective.51, 52 For anxiety, CBT is highly 
effective.53 For young people with anxiety who do not respond to this treatment, 
adjunctive antidepressant medication (i.e., fluoxetine) may also be helpful.54
In contrast, there is research evidence supporting the use of some newer 
antipsychotics to treat the other top two diagnoses — conduct disorders 
(including oppositional defiant disorder) and tic disorders. Risperidone can 
effectively treat both conduct and tic disorders, while quetiapine can reduce 
symptoms of conduct disorder. 31, 32, 41–46 
Evidence supporting the use of psychosocial treatments for both conditions 
also exists. Multiple RCTs have shown the effectiveness of numerous psychosocial 
treatments for conduct disorder — including parent training, family therapy and 
CBT.55, 56 Beyond the large number of high-quality studies supporting the use of 
these psychosocial treatments for conduct disorder, other advantages have been 
documented. Specifically, unlike antipsychotics, these psychosocial treatments 
Newer antipsychotics should 
only be used where there 
is solid evidence that the 
benefits exceed the risks.
REVIEW CoNTINUED
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have been shown to lead to enduring benefits once the treatment ends. They 
also do not have the detrimental side effects common with antipsychotics.19, 55, 56 
Regarding tic disorders, evidence supporting the use of psychosocial treatments 
was more limited. However, we still uncovered two RCTs which showed that 
behavioural treatments can significantly reduce tics in children and youth.57, 58
First do no harm
Prescribing newer antipsychotics to children and youth may lead to harm in 
several possible ways. Most importantly, if using these medications means that 
effective treatments are inadvertently withheld — particularly for anxiety, ADHD 
and depression — then young people may experience needless suffering. Similar 
issues apply if newer antipsychotics are offered for conduct, 
autism spectrum and tic disorders without first offering other 
(first-line) effective treatments. For example, antipsychotics should 
be considered for children with autism spectrum disorder who 
experience severe behavioural symptoms only after appropriate 
behavioural treatments have been tried without success.59 
Beyond inappropriate prescribing, there is also the question 
of basic safety. Newer antipsychotics, even in the short term, are 
associated with adverse health events for children and youth, 
including weight gain of 7 to 9 kilograms (15 to 20 pounds), 
abnormal blood glucose and lipid levels, and high blood 
pressure.19 In fact, a recent prospective study of BC young people 
found that treatment with newer antipsychotics was a significant 
predictor for developing “metabolic syndrome” — a serious 
medical disorder associated with significant cardiovascular risks, 
including the development of type 2 diabetes.60 Meanwhile, little 
is known about the longer-term effects of these medications, 
particularly when they are started early in life.61
Of course, no physician ever writes a prescription intending 
to cause harm. Still, given the side effect profiles of newer 
antipsychotics, the sharp rise in their prescriptions for children 
and youth has this potential — particularly if effective treatments 
are not being offered.7 Newer antipsychotics should therefore 
only be used where there is solid evidence that the benefits exceed 
the risks. The BC and Manitoba studies suggest that beyond 
individuals, there may also be a public health problem in that  
for too many children and youth, this careful deliberation is  
not occurring.
improving monitoring and prescribing
Given the significant metabolic side effects associated with newer antipsychotics, it is essential for practitioners 
to carefully monitor every child and youth taking these 
medications. Yet researchers at BC Children’s hospital found 
that even on inpatient units, only 32% of children were 
receiving such monitoring.62 
these researchers consequently developed a “metabolic 
monitoring protocol” for children being prescribed newer 
antipsychotics.60 their Metabolic assessment, screening and 
Monitoring tool identifies suggested intervals for measuring 
height, weight, waist circumference and blood pressure, as 
well as blood tests for assessing glucose, lipids, and liver 
and thyroid functioning.63 the use of this protocol was highly 
successful, increasing monitoring on the inpatient unit to 
89%.64 Following this effective inpatient implementation, 
training was then provided to community-based child and 
youth mental health teams in Vancouver.64
the gains made in the community-based clinics extended 
beyond significant increased monitoring.64 Perhaps even more 
importantly, newer antipsychotic prescriptions also decreased 
by 58% — including far fewer cases where these drugs 
were prescribed for disorders without regulatory approval or 
research evidence supporting their use.64 For example, before 
the training, 44% of children on these antipsychotics had a 
diagnosis of attention-deficit/hyperactivity disorder. After the 
training, this percentage fell to 24%.64  
Beyond BC, this screening tool has now been incorporated 
into Canadian pediatric and child psychiatry clinical guidelines 
for monitoring newer antipsychotics.64 this screening tool 
therefore has considerable potential to improve monitoring 
and prescribing — particularly for family physicians in  
primary care.
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Recommendations on using newer antipsychotics 
Based on this review of the research evidence, only four newer antipsychotics 
should be prescribed for children and youth, and only for the following five 
specific conditions. 
1.  For youth with schizophrenia who exhibit core symptoms of psychosis 
(risperidone or olanzapine).
2.  For youth with bipolar disorder who exhibit core symptoms of mania 
(risperidone, quetiapine or aripiprazole). 
3.  For youth with conduct disorders who exhibit core symptoms of severe 
aggressive behaviour — who have not responded to first-line treatments such 
as parent training, family therapy and CBT (risperidone or quetiapine).
4. For children and youth with autism spectrum disorder who exhibit 
challenging associated behaviours such as self-injury — who have not 
responded to first-line behavioural treatments (risperidone or aripiprazole). 
5. For children and youth with tic disorders — who have not responded to first-
line behavioural treatments (risperidone).
When prescribing any of these medications, the physician must also carefully 
monitor for side effects as well as benefits.
Beyond these specific uses, based on this review of the research evidence, 
newer antipsychotics are not recommended for children and youth. Instead, 
children and youth who experience anxiety, ADHD or depression should be 
offered effective first-line treatments for these conditions.
1.	 For children and youth with anxiety, CBT is the recommended first-line 
treatment, with fluoxetine being recommended for those who do not respond 
to CBT.
2.	 For children and youth with ADHD, stimulant medication is the 
recommended first-line treatment, with behavioural therapy and parent 
training also being effective.
3.	 For children and youth with depression, CBT is the recommended first-
line treatment, with interpersonal therapy also being effective, and with one 
antidepressant (fluoxetine) being recommended for those who do not respond 
to psychosocial treatments.
For more information on effective treatments for anxiety, ADHD and depression, 
please see previous issues of the Quarterly.
For youth, parents and practitioners: 
What if you are concerned about a 
prescription?
anyone — whether a youth, parent, teacher, health practitioner or social 
worker — concerned about a young person’s 
prescription should speak directly with the 
prescribing physician. Most physicians ought 
to welcome this kind of inquiry and should 
be willing to provide a thoughtful rationale 
for their choices. sharing this issue of the 
Quarterly may be helpful, too. in BC, you can 
also obtain additional good-quality health 
information from the following sources: 
•  healthlinkBC website
•  8-1-1 — BC’s free health information and 
advice line, which provides 24-hour access 
to nurses and other health professionals, 
such as pharmacists
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Let ters
When research findings 
and budgets collide  
To the Editors:
In your recent issue on children in mental health crisis, the two 
interventions reviewed were delivered by practitioners with caseloads 
limited to three families. Yet child and youth mental health clinics 
typically do not have the staffing levels to support such resource-intensive 
interventions. How can these research findings inform our practice with 
children who are in mental health crisis?
Cheryl Conant
Surrey, BC
It can be quite challenging to implement new interventions at the best of times, 
but it is particularly difficult when resources are limited. One interim approach 
is to review the core elements of successful programs — to compare the new 
approach with current practices, and to determine what can be feasibly delivered. 
For example, the two successful interventions that we reviewed in the last 
Quarterly — Home-Based Crisis Intervention (HBCI) and Multisystemic Therapy 
(MST) — both contained elements that most child and youth mental health 
practitioners know well. These include cognitive-behavioural therapy, family 
therapy and parent training, as well as crisis intervention planning. Practitioners 
can focus on these strategies when they work with children in crisis — as many 
already do. 
However, intensiveness is also a core element of these two interventions. For 
example, as you note, HBCI and MST both require strict limits on caseloads. This 
is likely an essential ingredient in the success of these programs, such that offering 
a less intensive version will not produce the same positive results. If this new 
approach cannot be feasibly delivered within existing resources, then a case needs 
to be made for more resources.
The bottom line is that research-informed practice requires adequate resources 
so that practitioners can indeed offer the best possible interventions for young 
people in need. For children in crisis, offering effective interventions such as 
HBCI and MST — with fidelity — may well save money in the long term, for 
example, by averting more costly hospital stays. But even more importantly, 
perhaps these interventions (and their intensiveness) need to be a model for 
expanding services and for organizing services differently — if children in crisis 
are not being well served.  
Contact Us
We hope you enjoy this issue.  
We welcome your letters and suggestions  
for future topics. Please email them to  
chpc_quarterly@sfu.ca  
or write to 
Children’s Health Policy Centre  
Attn: Jen Barican  
Faculty of Health Sciences 
Simon Fraser University  
Room 2435, 515 West Hastings St.  
Vancouver, British Columbia   
V6B 5K3
research-informed practice requires 
adequate resources so that practitioners 
can offer the best possible interventions for 
young people in need. 
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Methods
1.  Identifying studies on psychiatric prescribing patterns
To identify psychiatric prescribing patterns pertaining to Canadian children and 
youth, we conducted a comprehensive search for systematic reviews and original 
population-based studies (i.e., covering all children and youth in a given region). 
In addition to our usual literature scanning, we searched major databases using 
the following search strategy: 
Next we assessed all potentially relevant articles using the following inclusion 
criteria:
Using this approach, we identified three original studies — each assessing 
antipsychotic prescribing (one from BC and two from Manitoba). However, 
because there was considerable overlap between the two Manitoba studies, 
we extracted data from only the most recent one, which was also the most 
comprehensive.
2.  Identifying newer antipsychotics with  
Health Canada approval
We first identified all the second-generation antipsychotics (aripiprazole, 
clozapine, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone) 
tracked in the two included studies on prescribing patterns. To determine 
which had regulatory approval for use in children and youth, we then searched 
the Health Canada Drug Product Database and reviewed all relevant product 
monographs pertaining to these seven medications. 
Table 3: Search Strategy for Articles on Psychiatric Prescribing Patterns 
• Cochrane, CINAHL, ERIC, Medline and PsycINFO
• Off-label use and drug prescriptions
• Peer-reviewed articles published in English between 2003  
and 2013
• Child participants aged 18 years or younger
Sources
Search Terms
Limits
Table 4: Inclusion Criteria for Articles on Psychiatric Prescribing Patterns
• Relating to off-label prescription use or prescribing patterns in Canada
•  Describing both psychiatric medications and the diagnoses/conditions being treated
Basic Criteria
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3.  Identifying research evidence on newer antipsychotics 
We also conducted a comprehensive search to identify high-quality research 
evidence on the effectiveness of these seven second-generation antipsychotics for 
treating mental disorders in children and youth. Using methods adapted from 
the Cochrane Collaboration65 and Evidence-Based Mental Health,66 we applied the 
following search strategy:
We then applied the following inclusion criteria — requiring medications to 
meet all criteria to be included in our final review. 
Following the searches, two independent assessors reviewed all abstracts and 
all original retrieved articles — first reaching consensus on whether RCTs met the 
criteria, then reaching consensus on whether medications met the criteria. A final 
list of medications was then compiled.  
Table 5: Search Strategy for Research Evidence on Newer Antipsychotics
• Medline and PsycINFO
• Aripiprazole, clozapine, olanzapine, paliperidone, quetiapine,  
risperidone and ziprasidone
• Peer-reviewed articles published in English between 2003  
and 2013
• Child participants aged 18 years or younger
• Randomized controlled trial (RCT) methods used
Sources
Search Terms
 
Limits
For more information on our  
research methods, please contact
Jen Barican
chpc_quarterly@sfu.ca 
Children’s Health Policy Centre 
Faculty of Health Sciences  
Simon Fraser University
Room 2435, 515 West Hastings St. 
Vancouver, British Columbia
V6B 5K3 
Table 6: Inclusion Criteria for Research Evidence on Newer Antipsychotics
• Clear descriptions of participant characteristics, settings and medications
• Use of double-blinding procedures 
• Attrition rates below 20% at post-test or use of intention-to-treat analysis
• Outcome indicators relevant to specific mental health diagnoses
• Levels of statistical significance reported for all primary outcome indicators 
• Two or more double-blind RCTs available showing significant positive benefits
• At least one RCT available using placebo controls
Criteria for RCTs
Criteria for defining medication effectiveness
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